PMV Pharmaceuticals Inc. (PMVP): Price and Financial Metrics


PMV Pharmaceuticals Inc. (PMVP): $8.27

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PMVP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PMVP Stock Price Chart Interactive Chart >

Price chart for PMVP

PMVP Price/Volume Stats

Current price $8.27 52-week high $24.26
Prev. close $8.27 52-week low $7.57
Day low $8.22 Volume 230,946
Day high $8.42 Avg. volume 464,667
50-day MA $9.11 Dividend yield N/A
200-day MA $12.50 Market Cap 377.65M

PMV Pharmaceuticals Inc. (PMVP) Company Bio


PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.


PMVP Latest News Stream


Event/Time News Detail
Loading, please wait...

PMVP Latest Social Stream


Loading social stream, please wait...

View Full PMVP Social Stream

Latest PMVP News From Around the Web

Below are the latest news stories about PMV PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PMVP as an investment opportunity.

Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?

The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 8, 2022

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al

Yahoo | November 22, 2022

15 Most Shorted Stocks Right Now

In this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment […]

Yahoo | November 17, 2022

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022 Biotech industry veteran Dr. Carol Gallagher appointed to Board of Directors CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology com

Yahoo | November 8, 2022

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | November 5, 2022

Read More 'PMVP' Stories Here

PMVP Price Returns

1-mo 0.24%
3-mo -36.14%
6-mo -44.68%
1-year -47.66%
3-year N/A
5-year N/A
YTD -4.94%
2022 -62.34%
2021 -62.45%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7076 seconds.